. 2019 Feb 12;16(3):838–847. doi: 10.1007/s13311-019-00716-5

Table 2.

Patients’ characteristics

	Sex (w/m)	Age	Weight in kg	Height in cm	CSF protein in mg/dl	MRI	MRCSS	INCAT	Antibodies	First therapy
GBS	6/27	53 (3–83)	75 (18–100)	175 (110–195)	67.0 (32–205)	8/19*	52 (11–60)	4 (1–10)	GM1-IgG n = 3 GM4-IgG n = 2 GQ1b-IgG n = 2 Others n = 7	IVIG/PEx n = 24 None n = 1 IVIG-repeat n = 5 IVIG + steroids n = 2 Steroids n = 1
CIDP	12/22	58 (35–88)	80 (59–125)	179 (158–198)	71.5 (34–126)	7/21	57 (36–60)	3 (1–10)	GM1-IgG n = 2 Sulfatide n = 1 GM1-IgM n = 1	IVIG/Pex n = 5 IVIG-repeat n = 23 IVIG + steroids n = 2 Steroids n = 2 IVIG+IM = 2
p values	0.104	0.054	0.092	0.100	0.631	0.432	0.01	0.002	0.385

Sex (w/m)

Age

Weight in kg

Height in cm

CSF protein in mg/dl

MRI

MRCSS

INCAT

Antibodies

First therapy

GBS

6/27

53 (3–83)

75 (18–100)

175 (110–195)

67.0 (32–205)

8/19*

52 (11–60)

4 (1–10)

GM1-IgG n = 3

GM4-IgG n = 2

GQ1b-IgG n = 2

Others n = 7

IVIG/PEx n = 24

None n = 1

IVIG-repeat n = 5

IVIG + steroids n = 2

Steroids n = 1

CIDP

12/22

58 (35–88)

80 (59–125)

179 (158–198)

71.5 (34–126)

7/21

57 (36–60)

3 (1–10)

GM1-IgG n = 2

Sulfatide n = 1

GM1-IgM n = 1

IVIG/Pex n = 5

IVIG-repeat n = 23

IVIG + steroids n = 2

Steroids n = 2

IVIG+IM = 2

p values

0.104

0.054

0.092

0.100

0.631

0.432

0.01

0.002

0.385

p values < 0.05 are significant

GBS = Guillain–Barré syndrome; CIDP = chronic inflammatory demyelinating polyradiculoneuritis; CSF = cerebrospinal fluid; MRI = magnetic resonance imaging of the lumbar spine; IM = immunosuppressant; G = ganglioside, * = gadolinium enhancement/T2-hyperintensities in 8 of 19 vs. 7 of 21 performed MRI